CSRC approves Shenglong Stock's IPO registration on the Shenzhen Stock Exchange main board.
On January 9th, the China Securities Regulatory Commission issued the "Approval for Initial Public Offering Registration of Luoyang Shenglong Mining Group Co., Ltd."
On January 9th, the China Securities Regulatory Commission issued the "Approval of the Initial Public Offering of Shares of Luoyang Shenglong Mining Group Co., Ltd." It is reported that Shenglong shares plan to be listed on the main board of the Shenzhen Stock Exchange, with Guotou Securities as its sponsoring institution, planning to raise 1.53 billion yuan.
The prospectus shows that Shenglong shares is a large domestic molybdenum company, dedicated to the comprehensive development and utilization of non-ferrous metal mineral resources. During the reporting period, it mainly engaged in the production, processing, and sales of important strategic resources related to molybdenum products, with main products being molybdenum concentrate and molybdenum iron.
By the end of 2024, the company's reserves of molybdenum metal and molybdenum metal production in 2024 both accounted for more than 9% of the domestic market. According to data from the United States Geological Survey (USGS), in 2024, China's molybdenum metal production was about 110,000 tons, with the company's molybdenum metal production in 2024 being 10,600 tons, accounting for 9.64% of China's molybdenum metal production, making it one of China's important molybdenum suppliers.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


